Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MART-1 F5 TCR Engineered PBMC for Advanced Melanoma
NCT00910650Phase 2Completed
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Oct 2009
- Primary completion
- May 2019
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes in melanoma, sponsored by UCLA Jonsson Comprehensive Cancer Center. Started Oct 2009; status: completed.
02
Drugs
autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00910650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00910650.